ERBB2 and neoplasm: Although the cancer may change course during treatment due to pathway interaction and cross‐talk, it can be very helpful to determine the biological driver of the specific tumour (i.e., whether ER or HER2 signalling is dominating and driving the growth and advancement of the tumour).